Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qizhi Weitong Granules for Abdominal Pain in IBS-D
NCT05113888Phase 2Unknown
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Qizhi Weitong granules in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Primary endpoints: Abdominal pain intensity and Improvement of stool characteristics. Status: unknown.
02
Drugs
Qizhi Weitong granules
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05113888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113888.